The present invention relates to a therapeutic method for the treatment of
non-hematologic malignancies comprising administering anti-IGF-1R
antibodies, particularly human anti-IGF-1R antibodies, to a patient, in
conjunction with the administration of at least one other therapeutic
agent. The invention further relates to pharmaceutical compositions
comprising these antibodies and methods of using such compositions
thereof for treatment.